Scilex Holding Company Share-based Payment Arrangement, Expense
Scilex Holding Company (SCLX) reported Share-based Payment Arrangement, Expense of $15.69 million for the 12-month period ending 2024-12-31, per its 10-K filed 2025-03-31.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:AllocatedShareBasedCompensationExpense · last filed 2025-03-31
- Scilex Holding Company share-based payment arrangement, expense for the quarter ending 2024-12-31 was $4.80M.
- Scilex Holding Company share-based payment arrangement, expense for the quarter ending 2024-09-30 was $3.71M, a 5.90% increase year-over-year.
- Scilex Holding Company share-based payment arrangement, expense for the quarter ending 2024-06-30 was $3.61M, a 0.72% increase year-over-year.
- Scilex Holding Company share-based payment arrangement, expense for the quarter ending 2024-03-31 was $3.56M, a 4.35% decline year-over-year.
- Scilex Holding Company share-based payment arrangement, expense for fiscal 2024 was $15.69M, a 7.49% increase from fiscal 2023.
- Scilex Holding Company share-based payment arrangement, expense for fiscal 2023 was $14.60M, a 176.44% increase from fiscal 2022.
- Scilex Holding Company share-based payment arrangement, expense for fiscal 2022 was $5.28M, a 9.31% decline from fiscal 2021.
- Scilex Holding Company share-based payment arrangement, expense for fiscal 2021 was $5.82M, a 7.91% increase from fiscal 2020.
| Period end | Share-based Payment Arrangement, Expense 3 month | Share-based Payment Arrangement, Expense 6 month | Share-based Payment Arrangement, Expense 9 month | Share-based Payment Arrangement, Expense 12 month |
|---|---|---|---|---|
| 2024-12-31 | $4.80M derived: 10-K 12 month − 3 quarters · filed 2025-03-31 | $8.52M derived: sum of 2 quarters · filed 2025-03-31 | $12.13M derived: sum of 3 quarters · filed 2025-03-31 | $15.69M 10-K · filed 2025-03-31 |
| 2024-09-30 | $3.71M 10-Q · filed 2025-01-17 | $7.33M derived: sum of 2 quarters · filed 2025-01-17 | $10.88M derived: sum of 3 quarters · filed 2025-01-17 | |
| 2024-06-30 | $3.61M 10-Q · filed 2025-01-17 | $7.17M derived: sum of 2 quarters · filed 2025-01-17 | ||
| 2024-03-31 | $3.56M 10-Q · filed 2025-01-17 | |||
| 2023-12-31 | $14.60M 10-K · filed 2025-03-31 | |||
| 2023-09-30 | $3.51M 10-Q · filed 2025-01-17 | $7.09M derived: sum of 2 quarters · filed 2025-01-17 | $10.81M derived: sum of 3 quarters · filed 2025-01-17 | |
| 2023-06-30 | $3.59M 10-Q · filed 2025-01-17 | $7.31M derived: sum of 2 quarters · filed 2025-01-17 | ||
| 2023-03-31 | $3.72M 10-Q · filed 2025-01-17 | |||
| 2022-12-31 | $5.28M 10-K · filed 2024-03-12 | |||
| 2022-09-30 | $1.24M 10-Q · filed 2023-11-14 | $2.67M derived: sum of 2 quarters · filed 2023-11-14 | $4.03M derived: sum of 3 quarters · filed 2023-11-14 | |
| 2022-06-30 | $1.44M 10-Q · filed 2023-11-14 | $2.79M derived: sum of 2 quarters · filed 2023-11-14 | ||
| 2022-03-31 | $1.35M 10-Q · filed 2023-11-14 | |||
| 2021-12-31 | $5.82M 10-K · filed 2024-03-12 | |||
| 2020-12-31 | $5.39M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |